Second-line Chemotherapy with Paclitaxel and Carboplatin for Patients with Recurrent Ovarian Carcinoma

Seo, Hyung Joo; Lee, Chul Min; Kim, Jaung Sun; Lee, Hye Joo; Park, Yong Joo; Cho, Yong Kyoon; Choi, Hoon; Kim, Bok Rin; Lee, Hong Kyoon

Abstract

OBJECTIVE
This study is to investigate the efficacy and toxicity of paclitaxel plus carboplatin used as a salvage therapy.
METHODS
Between June 2000 and November 2003, 10 patients aged 43-74 (median 55.0) with recurrent ovarian carcinoma were given combination chemotherapy including paclitaxel and carboplatin. The subjects received initial chemotherapy with paclitaxel plus cisplatin/carboplatin. On recurrence, paclitaxel was administered intravenously at a dose of 175 mg/m2 with carboplatin by AUC 5 every 3 weeks. The median treatment cycle was 10 cycles (range, 1 to 15 cycles). Recurrence of ovarian carcinoma was determined by elevation of serum CA-125, or radiologic imaging. Responses and toxicities were evaluated according to Gynecologic Oncology Group criteria and Common Terminology Criteria for Adverse Events from NCI (National Cancer Institute).
RESULTS
The overall clinical response rate was 60.0% (6/10). Better response was observed in patients who were sensitive with initial chemotherapy. Anemia was the most frequent complication.
CONCLUSION
Paclitaxel and carboplatin has been shown to be a feasible agent in patients with recurrent ovarian cancer.